Microfluidics‐Enabled Nanovesicle Delivers CD47/PD‐L1 Antibodies to Enhance Antitumor Immunity and Reduce Immunotoxicity in Lung Adenocarcinoma

The CD47/PD‐L1 antibodies combination exhibits durable antitumor immunity but also elicits excessive immune‐related adverse events (IRAEs) caused by the on‐target off‐tumor immunotoxicity, hindering their clinical benefits greatly. Here, a microfluidics‐enabled nanovesicle using ultra‐pH‐sensitive p...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Zhenwei, Dong, Shaowei, Chen, Yao, Huang, Tuxiong, Qin, Bo, Yang, Qinhe, Jiang, Xingyu, Zou, Chang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10369263/
https://www.ncbi.nlm.nih.gov/pubmed/37132609
http://dx.doi.org/10.1002/advs.202206213

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10369263/
https://www.ncbi.nlm.nih.gov/pubmed/37132609
http://dx.doi.org/10.1002/advs.202206213

Ejemplares similares